Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Lansoprazole
Drug ID BADD_D01245
Description Lansoprazole marketed under the brand Prevacid, is a proton pump inhibitor (PPI) and is structurally classified as a substituted benzimidazole.[A177065] It reduces gastric acid secretion by targeting gastric H,K-ATPase pumps and is thus effective at promoting healing in ulcerative diseases, and treating gastroesophageal reflux disease (GERD) along with other pathologies caused by excessive acid secretion.[A177053]
Indications and Usage For the treatment of acid-reflux disorders (GERD), peptic ulcer disease, H. pylori eradication, and prevention of gastroinetestinal bleeds with NSAID use.
Marketing Status Prescription; OTC; Discontinued
ATC Code A02BC03
DrugBank ID DB00448
KEGG ID D00355
MeSH ID D064747
PubChem ID 3883
TTD Drug ID D06YYD
NDC Product Code 60687-111; 0113-7116; 68788-6390; 71335-0575; 38779-2289; 71335-0043; 0363-4069; 65015-658; 46122-698; 65628-080; 64764-046; 0093-7350; 11532-1441; 49035-373; 53104-7526; 62175-415; 72288-343; 52932-0730; 11673-117; 70700-263; 66332-1443; 0093-3009; 64679-140; 0904-6662; 55111-044; 64679-669; 49452-3041; 43598-560; 41520-816; 67877-275; 63629-2342; 59779-117; 67877-274; 11532-1440; 63629-4851; 68071-3019; 55111-399; 69256-401; 50090-4596; 50090-5180; 42291-433; 31722-571; 49348-301; 30142-288; 49711-0110; 0378-8015; 72288-829; 0113-0116; 68071-4456; 68382-772; 41250-391; 72288-301; 51838-123; 70700-262; 42765-023; 72476-020; 70771-1132; 68788-7742; 0378-8030; 0536-1324; 41250-117; 70677-0124; 31722-570; 59349-0015; 0536-1236; 63629-7552; 64764-541; 68071-5119; 63739-555; 71335-0917; 71052-242; 62175-430; 62756-252; 61919-890; 51927-3877; 68382-771; 68071-2274; 68001-111; 60687-123; 65841-770; 41163-117; 63981-582; 11822-0117; 62011-0472; 63187-510; 11822-3374; 69842-270; 62175-515; 70000-0508; 0781-2148; 0113-6002; 55154-0253; 63629-2340; 50090-2225; 55289-704; 56062-283; 27241-020; 36800-392; 0113-0117; 30142-117; 70771-1133; 72189-279; 71335-1820; 49035-739; 71335-1425; 79903-068; 27241-019; 0363-0739; 52562-021; 43598-561; 55111-739; 68788-7789; 30142-192; 63415-0060; 65372-1136; 63187-152; 45865-879; 45802-878; 65977-0013; 11673-280; 56062-117; 69842-755; 0781-2147; 50090-3195; 37012-117; 43598-883; 0067-6286; 16714-186; 62011-0168; 66332-1442; 42291-365; 51079-121; 68391-117; 80425-0174; 63850-3309; 63629-2341; 55910-117; 68001-112; 16571-698; 0378-6981; 63868-429; 0378-6982; 71335-1521; 46122-107; 16714-185; 64764-543; 16571-697; 36800-295; 51552-1239; 64764-544; 51927-0064; 0093-3008; 21130-181; 55154-4848; 57896-761; 63981-117; 42291-364; 55910-307; 45802-245; 69842-507; 64679-670; 16571-742; 68382-543; 0363-1419; 81522-001; 70000-0069; 68016-758; 80425-0148; 68382-544; 70756-806; 70756-807; 0113-1114; 0093-7351; 71335-0058; 42291-434; 41163-150; 68788-7385; 0378-3995; 51407-324; 65841-769; 49035-411; 72189-062; 37808-755; 64374-007; 0113-7003; 55111-398; 61919-245; 61919-655; 0363-1212; 60760-544; 36800-117; 71335-0105
Synonyms Lansoprazole | Lansoprazol | 2-(((3-Methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl)methyl)sulfinyl)benzimidazole | Lansoprazoles | Ogastro | AG 1749 | AG-1749 | AG1749 | Agopton | Bamalite | Lansol | Lansoprazole Sodium | Sodium, Lansoprazole | Lanzor | Monolitum | Opiren | Prevacid | Pro Ulco | Promeco | Takepron | Ulpax | Zoton | Ogast | Prezal
Chemical Information
Molecular Formula C16H14F3N3O2S
CAS Registry Number 103577-45-3
SMILES CC1=C(C=CN=C1CS(=O)C2=NC3=CC=CC=C3N2)OCC(F)(F)F
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Candida infection11.03.03.021--
Immune thrombocytopenic purpura10.04.01.008; 01.08.01.0070.001048%Not Available
Sinus node dysfunction02.03.03.0170.000419%
Multiple organ dysfunction syndrome08.01.03.0570.000547%
Anal incontinence17.05.01.021; 07.01.06.0290.000419%
Depersonalisation/derealisation disorder19.14.01.004--Not Available
Abnormal loss of weight14.03.02.0190.000629%Not Available
Adenocarcinoma gastric16.13.03.002; 07.21.02.0020.000419%Not Available
Gastric mucosal hypertrophy07.11.03.0060.000419%Not Available
Hyponatraemic syndrome14.05.04.0090.001048%Not Available
Rash papulosquamous23.03.08.0140.000419%Not Available
Squamous cell carcinoma of the tongue16.13.07.007; 07.21.07.0100.000164%Not Available
Tachycardia paroxysmal02.03.02.0280.000419%Not Available
Urine potassium decreased13.11.01.0550.001048%Not Available
Clostridium difficile infection11.02.02.0090.000629%Not Available
Urine phosphorus decreased13.11.01.0540.001257%Not Available
Allergy test positive13.06.03.0110.001467%Not Available
Palatal oedema07.05.04.0080.001467%Not Available
Subacute cutaneous lupus erythematosus23.03.02.020; 15.06.02.012; 10.04.03.0120.010476%Not Available
Sopor19.02.04.002; 17.02.04.021--Not Available
Putamen haemorrhage24.07.04.031; 17.08.01.0580.000419%Not Available
Communication disorder19.19.01.0080.000419%Not Available
Gastritis bacterial07.19.03.014; 11.02.01.0390.000419%Not Available
Gitelman's syndrome20.05.03.017; 14.05.01.009; 03.06.02.0060.001467%Not Available
Skin plaque23.03.03.0440.000419%Not Available
Coma scale abnormal13.07.03.0120.001048%Not Available
Urine magnesium decreased13.11.01.0530.001257%Not Available
Spinal pain17.10.01.020; 15.02.01.008; 08.01.08.0300.000419%Not Available
Gastrointestinal polyp haemorrhage24.07.02.046; 16.05.03.003; 07.20.01.0110.000629%Not Available
End stage renal disease20.01.03.0190.001530%Not Available
The 21th Page    First    Pre   21    Total 21 Pages